CN1150185C - 被杂环化合物取代的丙醇胺衍生物、其制备方法、含有所述化合物的药物组合物及其用途 - Google Patents

被杂环化合物取代的丙醇胺衍生物、其制备方法、含有所述化合物的药物组合物及其用途 Download PDF

Info

Publication number
CN1150185C
CN1150185C CNB998116351A CN99811635A CN1150185C CN 1150185 C CN1150185 C CN 1150185C CN B998116351 A CNB998116351 A CN B998116351A CN 99811635 A CN99811635 A CN 99811635A CN 1150185 C CN1150185 C CN 1150185C
Authority
CN
China
Prior art keywords
alkyl
phenyl
compounds
compound
pyridyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB998116351A
Other languages
English (en)
Chinese (zh)
Other versions
CN1321154A (zh
Inventor
W
W·弗里克
ϣ
R·基尔希
�������������
H·格罗姆毕克
H·霍耶尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Aventis Pharma Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Deutschland GmbH filed Critical Aventis Pharma Deutschland GmbH
Publication of CN1321154A publication Critical patent/CN1321154A/zh
Application granted granted Critical
Publication of CN1150185C publication Critical patent/CN1150185C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/74Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79Acids; Esters
    • C07D213/80Acids; Esters in position 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
CNB998116351A 1998-10-02 1999-09-18 被杂环化合物取代的丙醇胺衍生物、其制备方法、含有所述化合物的药物组合物及其用途 Expired - Fee Related CN1150185C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19845402A DE19845402B4 (de) 1998-10-02 1998-10-02 Mit Heterocyclen substituierte Propanolaminderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
DE19845402.3 1998-10-02

Publications (2)

Publication Number Publication Date
CN1321154A CN1321154A (zh) 2001-11-07
CN1150185C true CN1150185C (zh) 2004-05-19

Family

ID=7883184

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB998116351A Expired - Fee Related CN1150185C (zh) 1998-10-02 1999-09-18 被杂环化合物取代的丙醇胺衍生物、其制备方法、含有所述化合物的药物组合物及其用途

Country Status (21)

Country Link
US (1) US6303639B1 (https=)
EP (1) EP1117661B1 (https=)
JP (1) JP2002526539A (https=)
KR (1) KR100611030B1 (https=)
CN (1) CN1150185C (https=)
AR (1) AR021843A1 (https=)
AT (1) ATE267825T1 (https=)
AU (1) AU760412B2 (https=)
BR (1) BR9914266A (https=)
CA (1) CA2346083A1 (https=)
DE (2) DE19845402B4 (https=)
DK (1) DK1117661T3 (https=)
ES (1) ES2219065T3 (https=)
HK (1) HK1040249B (https=)
HU (1) HUP0103893A3 (https=)
PL (1) PL347105A1 (https=)
PT (1) PT1117661E (https=)
RU (1) RU2219176C2 (https=)
TR (1) TR200100895T2 (https=)
WO (1) WO2000020410A1 (https=)
ZA (1) ZA200102589B (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19845406C2 (de) * 1998-10-02 2001-10-18 Aventis Pharma Gmbh Substituierte 1,3-Diaryl-2-pyridin-2-yl-3-(pyridin-2-ylamino)- propanolderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
AU2002231688A1 (en) 2000-12-21 2002-07-01 Sanofi-Aventis Deutschland Gmbh Diphenyl azetidinone derivatives, method for the production thereof, medicaments containing these compounds, and their use
DE10064402A1 (de) * 2000-12-21 2002-06-27 Aventis Pharma Gmbh Diphenylazetidinonderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
PL366855A1 (en) * 2001-08-22 2005-02-07 Aventis Pharma Deutschland Gmbh Combination preparations of aryl substituted propanolamine derivatives with other active ingredients and the use thereof
US7161008B2 (en) * 2002-05-03 2007-01-09 Sanofi - Aventis Deutschland GmbH Optically active β-aminoketones, optically active 1,3-amino alcohols and processes for preparing them
DE10219987A1 (de) * 2002-05-03 2004-04-08 Aventis Pharma Deutschland Gmbh Optisch aktive β-Aminoketone, optisch aktive 1,3-Aminoalkohole und Verfahren zu deren Herstellung
GB0307918D0 (en) 2003-04-05 2003-05-14 Astrazeneca Ab Therapeutic use
RU2363699C2 (ru) * 2005-02-28 2009-08-10 Джапан Тобакко Инк. Новое производное аминопиридина с ингибиторной активностью в отношении syk.
CA2794018C (en) * 2010-03-24 2016-05-10 Medical University Of South Carolina Compositions and methods for the treatment of degenerative diseases
EP2575821B1 (en) 2010-05-26 2015-08-12 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
CN104023727B (zh) 2011-10-28 2017-04-05 鲁美纳医药公司 用于治疗小儿胆汁淤积性肝病的胆汁酸再循环抑制剂
CA2852957C (en) 2011-10-28 2020-08-04 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of hypercholemia and cholestatic liver disease
CN105228615A (zh) 2013-03-15 2016-01-06 鲁美纳医药公司 用于治疗巴雷特食管和胃食管返流疾病的胆汁酸再循环抑制剂
US20140275090A1 (en) 2013-03-15 2014-09-18 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of primary sclerosing cholangitis and inflammatory bowel disease
US11238759B1 (en) 2015-10-29 2022-02-01 Ward-Kraft, Inc. Single ply wristband with printable coating
US11232719B1 (en) 2019-09-04 2022-01-25 Ward-Kraft, Inc. Single ply wristband with printable coating
PL3923943T3 (pl) 2019-02-12 2024-12-09 Mirum Pharmaceuticals, Inc. Zależna od genotypu i dawki odpowiedź na asbti u pacjentów z niedoborem pompy eksportu soli żółciowych
USD988404S1 (en) 2020-02-14 2023-06-06 Rekon, Llc Wristband label form with single strap wristbands
USD941917S1 (en) 2020-02-18 2022-01-25 Ward-Kraft, Inc. Combination wristband label form with extender
USD967253S1 (en) 2020-02-26 2022-10-18 Ward-Kraft, Inc. Wristband form with extender

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1194273A3 (ru) * 1981-02-09 1985-11-23 Пфайзер Инк (Фирма) Способ получени пирбутерола или его аналогов
FI892341A7 (fi) * 1988-06-10 1989-12-11 Hoffmann La Roche Propanoliamiinijohdannaisia
DE19704243A1 (de) * 1997-02-05 1998-08-06 Bayer Ag Neue 2-Amino-substituierte Pyridine
DK0869121T3 (da) 1997-04-04 2004-09-20 Aventis Pharma Gmbh Hypolipidæmiske propanolaminderivater

Also Published As

Publication number Publication date
DK1117661T3 (da) 2004-08-30
US6303639B1 (en) 2001-10-16
HK1040249B (zh) 2005-04-01
JP2002526539A (ja) 2002-08-20
DE59909609D1 (de) 2004-07-01
ZA200102589B (en) 2002-02-27
ES2219065T3 (es) 2004-11-16
PT1117661E (pt) 2004-09-30
HUP0103893A3 (en) 2002-10-28
HUP0103893A2 (hu) 2002-05-29
EP1117661B1 (de) 2004-05-26
CN1321154A (zh) 2001-11-07
ATE267825T1 (de) 2004-06-15
EP1117661A1 (de) 2001-07-25
DE19845402B4 (de) 2005-04-07
CA2346083A1 (en) 2000-04-13
DE19845402A1 (de) 2000-04-13
HK1040249A1 (en) 2002-05-31
BR9914266A (pt) 2001-11-06
KR20010103593A (ko) 2001-11-23
TR200100895T2 (tr) 2001-12-21
AU6192599A (en) 2000-04-26
KR100611030B1 (ko) 2006-08-10
RU2219176C2 (ru) 2003-12-20
WO2000020410A1 (de) 2000-04-13
AU760412B2 (en) 2003-05-15
PL347105A1 (en) 2002-03-25
AR021843A1 (es) 2002-08-07

Similar Documents

Publication Publication Date Title
CN1150185C (zh) 被杂环化合物取代的丙醇胺衍生物、其制备方法、含有所述化合物的药物组合物及其用途
CN1135223C (zh) 芳基取代的丙醇胺衍生物、包含它们的药物和它们的用途
CN1145619C (zh) 1,4-苯并硫杂吖庚因衍生物、其制备方法、含有该化合物的药物及其用途
JP6602311B2 (ja) B型肝炎コアタンパク質アロステリックモジュレーター
EP2585066B1 (en) Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
JP6283033B2 (ja) ウイルス感染症およびさらなる疾患の処置のためのアシルアミノピリミジン誘導体
CN1882581A (zh) N-[杂芳基(哌啶-2-基)甲基]苯甲酰胺衍生物及其制备方法和它们的治疗应用
JP2006524662A5 (https=)
CN103619172A (zh) 作为syk抑制剂的氨基嘧啶
CN1199731A (zh) 丙醇胺衍生物、其方法、含有它们的药物组合物和其用途
CN1159305C (zh) 新的2-(n-氰基亚氨基)噻唑烷-4-酮衍生物
CN1390211A (zh) 带有羟乙酰基哌嗪取代基的噁唑烷酮化合物的苯甲酸酯
EA007335B1 (ru) Новые соединения и композиции как ингибиторы катепсина
CN1141940C (zh) 多环噻唑体系用于制备预防或治疗肥胖的药物的用途
CN1148362C (zh) 多环的2-氨基噻唑体系、它们的制备方法和包含这些化合物的药物
CN1391558A (zh) 取代1,3-二芳基-2-吡啶-2-基-3-(吡啶-2-基氨基)-丙醇衍生物、其制备方法、含有它们的药物组合物及其应用
CN1064865A (zh) 4-[(2-苯并噻唑基)甲氨基]-a-[(3,4-二氟苯氧基)甲基]-1-哌啶乙醇
CN1349404A (zh) 多环2-氨基噻唑体系在预防或治疗肥胖的药物制备中的用途
WO2023116734A1 (en) Fused pyrrolidine compounds and compositions for treatment of respiratory viral infections
CN1149205C (zh) 多环的噻唑体系和它们作为减食欲剂的用途
CN1144801C (zh) 玻璃状已知缓激肽拮抗剂
CN1142777C (zh) 噁唑烷酮衍生物在治疗牛皮癣、关节炎和减少癌症化学疗法毒性中的应用
CN1312809A (zh) N-取代的氮杂二环庚烷衍生物及其制备方法和用途
CN1946712A (zh) 吡咯烷衍生物
CN1159306C (zh) 取代的8,8a-二氢-3aH-茚并[1,2-d]噻唑、它们的制备方法和它们作为药物的用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1040249

Country of ref document: HK

C56 Change in the name or address of the patentee

Owner name: SANOFI- AVENTIS GERMAN CO., LTD.

Free format text: FORMER NAME OR ADDRESS: AVENTIS PHARMACY (GERMANY)INTERNATIONAL CO., LTD.

CP01 Change in the name or title of a patent holder

Address after: Frankfurt, Germany

Patentee after: Hoechst Marion Roussel de GmbH

Address before: Frankfurt, Germany

Patentee before: Awentis Medicines Deutschland GmbH

C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee